Full-Time

Associate Director Pharmacovigilance Clinical Quality Audits & Compliance

Updated on 3/19/2025

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops therapies for neurological disorders

Compensation Overview

$143k - $178.3k/yr

+ Discretionary Bonus + Equity Awards

Senior, Expert

Princeton, NJ, USA + 1 more

More locations: San Diego, CA, USA

Hybrid model requires this role to work in the office three days per week on average.

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • Bachelor’s degree in a scientific field or related field.
  • Minimum of 10 years as lead auditor in Pharmacovigilance and Clinical trials
  • Five (5) years of projects and audit management responsibilities in the biopharmaceutical industry.
  • Must have strong background and experience in GVP/GCP compliance applicable to Global GVP and GCP regulatory requirements.
  • An equivalent combination of relevant education and experience may be considered.
Responsibilities
  • Conducts Pharmacovigilance and Clinical audits for studies and postmarketed products per EMA, FDA and MHRA regulations and guidelines.
  • Plan, execute and complete Pharmacovigilance audit program based on risk assessment for all marketed products, clinical trials, vendors, and critical computerized systems and internal processes for ensuring adequate sponsor oversight in compliance EMA, FDA and MHRA regulation and guidelines.
  • Audit activities include all aspects of planning, conducting, reporting, observations follow up and procedural documentation associated with internal and external audits and resource planning necessary to complete all audits. Ensure compliance to GVP, and GCP Quality Systems involving training, document management (SOPs and other controlled documents), change control, process improvement, and quality Quality systems activities will be coordinated with the Quality Systems group.
  • Support regulatory inspections including, but not limited to, FDA, EMA, and other regulatory bodies as Provides management with updates and status responses to regulatory inspections.
  • May act as Quality Assurance representative to assigned clinical studies and other development teams to ensure compliance with applicable regulations and industry guidance.
  • Manage audit and quality systems for GVP/GCP functions including resource planning, budgeting and forecast support.
  • Other duties as assigned.
Desired Qualifications
  • Exposure and collaboration with Drug Safety and Pharmacovigilance, Clinical Development and Operations as well as Medical Affairs and commercial stakeholders for marketed products such as Patient Access Program, and Specialty Pharmacies.
  • Acumen and ability in GVP/GCP auditing, FDA and EMA regulations inclusive of direct experience with Pharmacovigilance, clinical trials and System Development Life Cycle activities.
  • Excellent communication skills, both verbal and written with the ability to work independently as well as in a cross-functional, multi-cultural team with limited direction.
  • String knowledge of applicable GVP and GCP domestic and international regulations and guidelines for clinical trials.
  • Knowledge of GVP and GCP applicable domestic and international compliance audit concepts.
  • Ability to interpret and apply practical knowledge of regulations and guidelines for the immediate resolution of compliance.
  • Ability to assess regulatory/compliance risk, identify areas of improvement and propose practical solutions. Ability to interact successfully with internal and external stakeholders including Clinical Development, Regulatory Affairs, Drug Safety and Pharmacovigilance, Legal, Commercial, Sales and Marketing, etc.
  • Skilled at negotiating with business partners or management and influencing leaders regarding matters of significance to the organization.
  • Proficient at creating and communicating a clear vision among team members effectively aligning resources and activities to achieve functional area and/or organizational goals.
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these conditions while also promoting diversity and inclusion within their operations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's DAYBUE is now available for treating Rett syndrome in the U.S.
  • The partnership with Neuren Pharmaceuticals strengthens Acadia's position in the rare disease market.
  • Increased focus on personalized medicine benefits Acadia's tailored CNS disorder therapies.

What critics are saying

  • A class action lawsuit could lead to financial liabilities and reputational damage.
  • Increased competition in CNS treatments may impact Acadia's market share.
  • Reliance on partnerships poses risks if collaborations face challenges or fail.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on CNS disorders with a strong pipeline of small molecule drugs.
  • The company has a unique partnership with Stoke Therapeutics for RNA-based therapies.
  • Acadia's documentary series raises awareness for Rett syndrome, enhancing its community engagement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

2%
Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Yahoo Finance
Aug 15th, 2024
Ryan Reynolds Announces More To Parkinson'S(R) Campaign

Ryan & Tammy Reynolds (Photo: Business Wire)Acadia Parkinson's Fact Sheet-- The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions-- Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their familySAN DIEGO, August 14, 2024--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson’s disease – Parkinson’s-related hallucinations and delusions.Notably, around half of the people living with Parkinson’s disease may develop hallucinations or delusions over the course of their disease, but up to 90% of people currently do not proactively tell their physicians about these symptoms.1-3 By sharing their experiences caring for Ryan’s father, James "Jim" Reynolds, who passed away nearly a decade ago, Ryan and his mother Tammy, aim to raise awareness, educate and drive conversation between people with Parkinson’s disease, their families and their doctors about how best to talk about and treat these non-motor symptoms."My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease," Reynolds explains. "Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease."This press release features multimedia